Cybin (NASDAQ:HELP) Issues Earnings Results

Cybin (NASDAQ:HELP) released its quarterly earnings results on Friday. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.19), Zacks reports.

Cybin Price Performance

Shares of NASDAQ HELP opened at $6.09 on Friday. The firm has a market capitalization of $303.85 million, a PE ratio of -1.44 and a beta of 0.63. Cybin has a 1 year low of $4.81 and a 1 year high of $10.59. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.58 and a quick ratio of 8.58.

Analysts Set New Price Targets

Separately, Jefferies Financial Group assumed coverage on Cybin in a report on Monday, February 2nd. They issued a “buy” rating and a $22.00 target price on the stock. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Cybin has a consensus rating of “Buy” and an average target price of $22.00.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.